Drug Type Small molecule drug |
Synonyms TGRX 678, TGRX678 |
Target |
Mechanism Bcr-Abl T315I inhibitors(BCR-ABL T315I mutation inhibitors) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization ![]() |
Active Organization ![]() |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
RegulationBreakthrough Therapy (CN) |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Aggressive-Phase Chronic Myelocytic Leukemia | Phase 2 | CN | Shenzhen TargetRx, Inc.Startup | 05 Jun 2024 |
Philadelphia chromosome positive chronic myelogenous leukemia | Phase 1 | CN | Shenzhen TargetRx, Inc.Startup | 29 Mar 2021 |
refractory chronic myelocytic leukemia | Phase 1 | CN | Shenzhen TargetRx, Inc.Startup | 29 Mar 2021 |
Phase 1 | 95 | oiqmbxggku(ozbkzrukaf) = gxtynidsnr yltsbhxint (eqjwhvkowk ) View more | - | 11 Dec 2023 |